Evolution of fibrinogen-coated collagen patch for use as a topical hemostatic agent

被引:41
作者
Erdogan, Deha [1 ]
van Gulik, Thomas M. [1 ]
机构
[1] Acad Med Ctr, Dept Surg, Amsterdam, Netherlands
基金
英国生物技术与生命科学研究理事会;
关键词
tissue management; sealing; hemostasis; biomaterials; fibrinogen-coated collagen patch; topical hemostatic agent;
D O I
10.1002/jbm.b.30916
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Human fibrinogen and thrombin have been combined and coated onto a collagen patch for use as a topical hemostatic agent. These agents have now been used for many years to induce rapid hemostasis and tissue sealing after various indications including thoracic-, plastic-, pediatric-, liver-, and minimally invasive surgery. The only ready-to-use fibrinogen-coated collagen patch at this moment, the third-generation surgical patch (SP-3), contains no bovine aprotinin (antifibrinolytic protein) in contrast to its precursor SP-2, and is thus devoid of bovine-derived components. In vitro studies have shown equal bioequivalence between SP-2 and SP-3. Various experiments in animal models under normal, stressful, and hyperfibrinolytic conditions showed that SP-3 has comparable tissue sealing properties and also outperformed fibrin sealants alone in some studies. The results from these pre-clinical bridging studies showed that aprotinin is not essential for the therapeutic efficacy of SP-3. In conclusion, SP-3 has evolved into a rapid, ready-to-use adjunct to primary measures for tissue sealing and hemostasis, suitable in cardiovascular-, thoracic-, neuro-, spleen-, kidney-, and liver-surgery. (c) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:272 / 278
页数:7
相关论文
共 42 条
  • [1] Agus GB, 1996, INT SURG, V81, P316
  • [2] Seven hundred forty-seven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection
    Belghiti, J
    Hiramatsu, K
    Benoist, S
    Massault, PP
    Sauvanet, A
    Farges, O
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 191 (01) : 38 - 46
  • [3] The effects of fibrin
    Bergel, S
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1909, 35 : 663 - 665
  • [4] BRAUN F, 1975, WIEN KLIN WOCHENSCHR, V87, P815
  • [5] Carbon RT, 2002, TISSUE ENGINEERING AND BIODEGRADABLE EQUIVALENTS: SCIENTIFIC AND CLINICAL APPLICATIONS, P587
  • [6] Carbon RT, 2004, PROCEEDINGS OF THE 6TH WORLD CONGRESS ON TRAUMA, SHOCK, INFLAMMATION AND SEPSIS- PATHOPHYSIOLOGY, IMMUNE CONSEQUENCES AND THERAPY, P257
  • [7] Evaluating the in vitro adhesive strength of biomaterials. Biosimulator for selective leak closure
    Carbon, RT
    Baar, S
    Kriegelstein, S
    Huemmer, HP
    Baar, K
    Simon, SI
    [J]. BIOMATERIALS, 2003, 24 (08) : 1469 - 1475
  • [8] Massive liver haemorrhage and rupture caused by HELLP-syndrome treated by collagen fleeces coated with fibrin glue
    Cerwenka, H
    Bacher, H
    Werkgartner, G
    El-Shabrawi, A
    Mischinger, HJ
    [J]. EUROPEAN JOURNAL OF SURGERY, 1998, 164 (09) : 709 - 711
  • [9] Sealing of the mediastinum with a local hemostyptic agent reduces chest tube duration after complete mediastinal lymph node dissection for stage I and II non-small cell lung carcinoma
    Czerny, M
    Fleck, T
    Salat, A
    Zimpfer, D
    Klepetko, W
    Wolner, E
    Mueller, MR
    [J]. ANNALS OF THORACIC SURGERY, 2004, 77 (03) : 1028 - 1032
  • [10] Czerny M, 2000, J CARDIOVASC SURG, V41, P553